ArticleBMJ open2018
B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of
Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03089086 (South Australian Meningococcal B Vaccine Herd Immunity Study), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
South Australian Meningococcal B Vaccine Herd Immunity Study
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Social and behavioral predictors of two-doses 4CMenB vaccine series among adolescents enrolled in a cluster randomized controlled trial in Australia.Human vaccines & immunotherapeutics · 2022Trial
- Trial
- Direct whole-genome sequencing enables strain typing of unculturableMicrobial genomics · 2025Article
- Article
- The genomic epidemiology ofThe Lancet regional health. Western Pacific · 2024Article
- Geographical distribution of invasive meningococcal disease and carriage: A spatial analysis.Epidemiology and infection · 2024Article
- Childhood vaccine hesitancy in two regions with different socioeconomic backgrounds in Turkey.Zeitschrift fur Gesundheitswissenschaften = Journal of public health · 2023Article
- Exploring the Ability of Meningococcal Vaccines to Elicit Mucosal Immunity: Insights from Humans and Mice.Pathogens (Basel, Switzerland) · 2021Review
- Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.Human vaccines & immunotherapeutics · 2021Article
- Economic evaluation of meningococcal vaccines: considerations for the future.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Article
- Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019Review
- B Part of It study: a longitudinal study to assess carriage of Neisseria meningitidis in first year university students in South Australia.Human vaccines & immunotherapeutics · 2019Article
- UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence.Wellcome open research · 2019Article
- Exploitation ofFrontiers in immunology · 2019Review
- Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens.Wellcome open research · 2018Article
- Lessons from a community vaccination programme to control a meningococcal disease serogroup W outbreak in remote South Australia, 2017.Western Pacific surveillance and response journal : WPSARArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSouth Australia (SA) has the highest notification rate of invasive meningococcal disease in Australia with the majority of cases due to serogroup B. METHODS AND ANALYSIS: This is a parallel cluster randomised controlled trial enrolling year 10, 11 and 12 school students (approximately 16-18 years of age) throughout SA, in metropolitan and rural/remote areas. Schools are randomised to intervention (4CMenB vaccination at baseline) or control (4CMenB vaccination at study completion) with randomisation stratified by school size and socioeconomic status, as measured by the Index of Community Socio-Educational Advantage (Australian Curriculum). Oropharyngeal swabs will be taken from all students at visit 1, and 12 months later from year 11 and 12 students. Students unvaccinated in 2017 will receive vaccine at the 12-month follow-up. Carriage prevalence of ETHICS AND DISSEMINATION: The study was approved by the Women's and Children's Health Network Human Research Ethics Committee (WCHN HREC). The protocol, informed consent forms, recruitment materials, social media and all participant materials have been reviewed and approved by the WCHN HREC and updated on ClinicalTrials.gov. Results will be published in international peer-reviewed journals and presented at national and international conferences. The study findings will be provided in public forums and to study participants and participating schools. TRIAL REGISTRATION NUMBER: ACTRN12617000079347. NCT03089086; Pre-results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.